Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients

BACKGROUND: The tumor mutational burden (TMB) is a promising biomarker for immune checkpoint inhibitor (ICI). However, its relationships with clinical parameters have not been fully explored. We aimed to assess potential factors including age, microsatellite instability (MSI) state, tumor types, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lin, Chen, Chuan, Liu, Chaojun, Niu, Li, Pan, Chunguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908122/
https://www.ncbi.nlm.nih.gov/pubmed/35280376
http://dx.doi.org/10.21037/atm-22-358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908122/
https://www.ncbi.nlm.nih.gov/pubmed/35280376
http://dx.doi.org/10.21037/atm-22-358

Ejemplares similares